| Nov 6 |
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
LENZ Therapeutics GAAP EPS of -$0.38
|
| Nov 6 |
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
|
| Oct 30 |
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
|
| Oct 28 |
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
|
| Oct 28 |
LENZ reports positive Chinese study data for far-sightedness drug
|
| Oct 28 |
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Oct 28 |
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
|
| Oct 22 |
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
|
| Oct 21 |
FDA accepts LENZ application for far-sightedness drug LNZ100
|
